COO of Mayo Clinic Platform Believes De-identified Data Leads to Loss of Utility for Pharma, Other Third Parties - MedCity News
Maneesh Goyal, COO of Mayo Clinic Platform, emphasizes the need for stronger patient data privacy beyond traditional de-identification by employing a method that involves creating fictitious identities and using a secure "clean room" environment for data access, allowing pharma companies to conduct synthetic clinical trials and research without compromising patient privacy.
For someone engaged in healthtech and biotech, the Mayo Clinic Platform's "Orchestrate" offers an innovative solution for securely leveraging real-world patient data. By using advanced de-identification techniques and a controlled environment for data access, the platform enables pharma and medtech companies to run synthetic clinical trials and validate hypotheses without compromising patient privacy. This approach not only accelerates drug discovery and development processes but also significantly reduces wasted resources in clinical trials, providing a compelling investment opportunity and a model for future health data utilization.